Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12210946 | 0.80 | HDAC6 (0.41) | HDAC6HDAC8HDAC1HDAC3HDAC7 | |
| SCHEMBL12210759 | 0.78 | GRM1 (0.44) | HDAC6HDAC8HDAC1HDAC3HDAC7 | |
| SCHEMBL2519323 | 0.78 | HDAC6 (0.53) | HDAC6HDAC8HDAC1HDAC3HDAC7 | |
| SCHEMBL12211086 | 0.78 | HDAC6 (0.47) | HDAC6HDAC8HDAC1HDAC3HDAC7 | |
| SCHEMBL12210784 | 0.77 | HDAC6 (0.64) | HDAC6HDAC8HDAC1HDAC3HDAC7 | |
| SCHEMBL2522196 | 0.76 | HDAC6 (0.67) | HDAC6HDAC8HDAC1HDAC3HDAC7 | |
| SCHEMBL12211089 | 0.74 | HDAC6 (0.48) | HDAC6HDAC8HDAC1HDAC3HDAC7 | |
| SCHEMBL16418255 | 0.73 | HDAC6 (0.44) | HDAC6HDAC8HDAC1HDAC3HDAC7 | |
| SCHEMBL12210803 | 0.73 | HDAC6 (0.67) | HDAC6HDAC8HDAC1HDAC3HDAC7 | |
| SCHEMBL12283635 | 0.72 | HDAC6 (0.41) | HDAC6HDAC8HDAC1HDAC3HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946223-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | claimed |
| US-20150175614-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-8946223-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175614-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | HDAC6 1/4885HDAC8 17/4885HDAC1 2/4885 |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | HDAC6 1/4885HDAC8 17/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.